Johnson-Matthey-invests-in-Fine-Chemicals-with-expanded-facility-in-Cambridge-UK

Johnson Matthey invests in Fine Chemicals with expanded facility in Cambridge, UK

The investment allows us to work more closely with our customers and create strong partnerships in the Pharma and Biotech industries

23 May 2016

Johnson Matthey Fine Chemicals has celebrated the official opening of its expanded Cambridge facility. More than 30 customers and industry representatives joined staff for the opening on 4 May.

Sir Simon Campbell, former President of the Royal Society of Chemistry cut the ribbon to open the new space.

A focus on customer partnerships

Sir Simon congratulated Johnson Matthey for having the confidence and vision to make this significant investment, and said there was an increasing focus in the industry on quality, close connectivity and creativity, with genuine partnerships replacing the old customer and provider model.

This development responds to the evolving needs of both Pharma and Biotech on a worldwide scale

"This development responds to the evolving needs of both Pharma and Biotech on a worldwide scale," he said.

"Johnson Matthey is clearly responding to changing circumstances and has a strong vision, to grow organically and inorganically in the pharmaceutical customer development space and become a global leader.

"The integrated drug discovery and development capabilities we will now see will add significant value and attract highly quality customers nationally and internationally."

Attendees then toured the site's new laboratories and listened to presentations from industry experts and senior staff including General Manager of Johnson Matthey European Pharma Solutions, Dr Bernhard Paul.

Fine Chemicals at Johnson Matthey

Cambridge is one of the eleven global sites within the Fine Chemicals Division. Teams of scientists work collaboratively across these sites to deliver products and services through four core offerings: Custom Pharma Solutions, Catalysts, Controlled Substances, and APIs & Life Cycle Management. The Cambridge site also includes the Pharmorphix solid form sciences business, which Johnson Matthey acquired in October 2015.